

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
2003-0867SERIAL NO.  
10/600,640LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)APPLICANT  
Akira FUJISHIMA et al.

Date Submitted to PTO: December 22, 2004

FILING DATE  
June 23, 2003GROUP  
1625


## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AJ						
	AK						
	AL						
	AM						
	AN						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	Chemical Abstract CA 125:185465 of article of: B. I. Hirschowitz, "Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome," <u>Alimentary Pharmacology and Therapeutics</u> , Vol. 10, No. 4, pp. 507-522, 1996.
	AP	
	AQ	

EXAMINER

DATE CONSIDERED

1/25/05

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

ATTY DOCKET NO.  
2003-0867SERIAL NO.  
10/600,640U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEAPPLICANT  
Akira FUJISHIMA et al.LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)FILING DATE  
June 23, 2003GROUP  
1625

Date Submitted to PTO: January 7, 2005


## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AJ							
	AK							
	AL							
	AM							
	AN							

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	B. I. Hirschowitz et al., "Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome," Alimentary Pharmacology and Therapeutics, Vol. 10, No. 4, pp. 507-522, 1996.
	AP	
	AQ	

EXAMINER

DATE CONSIDERED

1/25/05